PUBLISHER: The Business Research Company | PRODUCT CODE: 1957750
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957750
Retinal disorder treatment refers to medical interventions and procedures aimed at managing or improving symptoms associated with retinal disorders. These disorders involve abnormalities or damage to the retina, the light-sensitive tissue at the back of the eye responsible for transmitting visual signals to the brain.
The main types of retinal disorder treatments include macular degeneration, diabetic retinopathy, and others. Macular degeneration, often called age-related macular degeneration (AMD), is a chronic eye condition that primarily affects the macula, the central part of the retina responsible for sharp central vision. Treatments are available in various dosage forms, including gels, eye solutions, capsules, tablets, eye drops, and ointments, and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies.
Tariffs have created notable challenges for the retinal disorder treatment market by increasing costs associated with importing active pharmaceutical ingredients, biologics, medical devices, and ophthalmic diagnostic equipment. These cost pressures have impacted drug manufacturing and distribution, particularly affecting injectable therapies, advanced dosage forms, and hospital pharmacy channels. Regions heavily dependent on imports, such as parts of Asia-Pacific, Latin America, and emerging Middle Eastern markets, are most affected by tariff-related supply chain disruptions. However, tariffs have also encouraged local manufacturing, regional sourcing of raw materials, and strategic partnerships, supporting long-term supply resilience and localized production capabilities.
The retinal disorder treatment market research report is one of a series of new reports from The Business Research Company that provides retinal disorder treatment market statistics, including retinal disorder treatment industry global market size, regional shares, competitors with a retinal disorder treatment market share, detailed retinal disorder treatment market segments, market trends and opportunities, and any further data you may need to thrive in the retinal disorder treatment industry. This retinal disorder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The retinal disorder treatment market size has grown strongly in recent years. It will grow from $13.69 billion in 2025 to $14.86 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to rising prevalence of age-related macular degeneration, increasing diabetic population globally, growth in ophthalmology clinics and specialty hospitals, advancements in retinal imaging technologies, improved awareness of retinal diseases.
The retinal disorder treatment market size is expected to see strong growth in the next few years. It will grow to $21.27 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to development of long-acting retinal drugs, increasing approval of novel biologics and gene therapies, expanding access to eye care in emerging markets, rising investment in ophthalmic research, growing demand for personalized retinal treatments. Major trends in the forecast period include growing adoption of anti-VEGF therapies, shift toward minimally invasive retinal procedures, increasing preference for sustained-release drug formulations, expansion of combination therapy approaches, rising use of home-based vision monitoring tools.
The rising prevalence of diabetes is expected to drive growth in the retinal disorder treatment market in the coming years. Diabetes is a chronic condition characterized by elevated blood glucose levels, caused by the body's inability to produce enough insulin or use it effectively. Diabetic retinopathy, the most common retinal disorder among diabetic patients, results from damage to retinal blood vessels, leading to bleeding, fluid leakage, and abnormal blood vessel growth. Retinal disorder treatments often use lasers to seal leaking vessels or eliminate abnormal ones. For example, in June 2024, the National Health Service (NHS), a UK-based government department, reported that in 2023, over 549,000 additional individuals in England were identified at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330, up from 3,065,825 in 2022. The growing prevalence of diabetes is therefore boosting demand for retinal disorder treatments.
Key players in the retinal disorder treatment market are focusing on innovative therapies, such as treatments for geographic atrophy, to expand their customer base, increase sales, and enhance revenue. Geographic atrophy therapies aim to manage symptoms, slow disease progression, and support patients coping with visual impairment. For instance, in August 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, announced FDA approval for IZERVAY. IZERVAY, a complement C5 inhibitor, is the first approved therapy for geographic atrophy (GA) to show a statistically significant reduction (p<0.01) in GA progression at the 12-month primary endpoint in two Phase 3 trials, establishing it as an effective treatment for GA secondary to age-related macular degeneration (AMD).
In July 2023, Astellas Pharma Inc. acquired Iveric Bio Inc., a US-based biopharmaceutical company specializing in retinal disease therapies, for an undisclosed amount. This acquisition enables Astellas to strengthen its presence in ophthalmology, access innovative treatments for retinal disorders, and reinforce its position in the market for vision-related therapies.
Major companies operating in the retinal disorder treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Regeneron Pharmaceuticals Inc., Genentech Inc., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Adverum Biotechnologies Inc., Kodiak Sciences Inc., Acucela Inc., IVERIC bio Inc., Oxurion NV, Graybug Vision Inc., Clearside Biomedical Inc., Ophthotech Corporation, Opthea Limited, PanOptica Inc., ThromboGenics NV
North America was the largest region in the retinal disorder treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal disorder treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the retinal disorder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The retinal disorder treatment market includes revenues earned by entities by providing retinal detachment, laser treatment, genetic treatments, and photodynamic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Retinal Disorder Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses retinal disorder treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for retinal disorder treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The retinal disorder treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.